Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low-dose diclofenac potassium in U.K.

This article was originally published in The Tan Sheet

Executive Summary

The Medicines and Healthcare Products Regulatory Agency moves a low dosage of diclofenac potassium, a non-steroidal anti-inflammatory drug, from prescription-only status to pharmacy class. Diclofenac potassium 12.5 mg tablets may be supplied without a prescription - similar to what is called "behind the counter" in the U.S. - to adults and children ages 14 and up to provide short-term relief from headaches, symptoms associated with flu or cold and mild to moderate pain relief, according to a July 8 update by MHRA. Diclofenac potassium is available in the U.S. only in 50 mg prescription products, according to FDA records...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel